Sugi Predict

Sugi Predict / Compounds / SCHEMBL10125779

SCHEMBL10125779

SCHEMBL10125779

CC(=O)[C@H](N)CCNC(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ANPEP P15144 4/20 0.35
▸ RNPEP Q9H4A4 3/20 0.35
▸ DNPEP Q9ULA0 3/20 0.35
▸ ARG1 P05089 1/20 0.33
▸ ARG2 P78540 1/20 0.33
▸ DPP7 Q9UHL4 2/20 0.32
▸ KISS1R Q969F8 1/20 0.32
▸ SLC15A1 P46059 1/20 0.32
▸ GABRP O00591 2/20 0.32
▸ GABRD O14764 2/20 0.32
▸ GABRA1 P14867 2/20 0.32
▸ GABRB1 P18505 2/20 0.32
▸ GABRG2 P18507 2/20 0.32
▸ GABRB3 P28472 2/20 0.32
▸ GABRA5 P31644 2/20 0.32
▸ GABRA3 P34903 2/20 0.32
▸ GABRA2 P47869 2/20 0.32
▸ GABRB2 P47870 2/20 0.32
▸ GABRA4 P48169 2/20 0.32
▸ GABRE P78334 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18720622 0.86 DPP7 (0.41) ANPEPRNPEPDNPEPDPP7SLC15A1
SCHEMBL18720628 0.86 DPP7 (0.41) ANPEPRNPEPDNPEPDPP7SLC15A1
SCHEMBL18720629 0.86 DPP7 (0.41) ANPEPRNPEPDNPEPDPP7SLC15A1
SCHEMBL13456695 0.84 DPP7 (0.33) ANPEPRNPEPDNPEPDPP7
SCHEMBL13456696 0.84 DPP7 (0.33) ANPEPRNPEPDNPEPDPP7
SCHEMBL25406097 0.83 SLC1A3 (0.46) SLC7A5SLC1A3SLC1A2SLC1A1
SCHEMBL2236935 0.83 SLC1A3 (0.46) SLC7A5SLC1A3SLC1A2SLC1A1
SCHEMBL2236943 0.83 SLC1A3 (0.46) SLC7A5SLC1A3SLC1A2SLC1A1
SCHEMBL12438071 0.81 GABRP (0.35) ANPEPRNPEPDNPEPARG1ARG2
SCHEMBL10110759 0.81 GABRP (0.35) ANPEPRNPEPDNPEPARG1ARG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119677-B2 Polyamides containing amino butyric acid-based building blocks NANOVIR, LLC (US) 2012-02-21 — — US disclosed
US-20100015084-A1 Compounds for Treating Papilloma Virus Infection NANOVIR, LLC (US) 2010-01-21 — — US disclosed
US-20090306164-A1 Methods for Treating Papilloma Virus Infection NANOVIR, LLC (US) 2009-12-10 — — US disclosed
US-7589171-B2 Polyamides for treating human papilloma virus NANOVIR, LLC (US) 2009-09-15 — — US disclosed
US-20070293417-A1 Polyamides for treating human papilloma virus NANOVIR, LLC 2007-12-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306164-A1 Methods for Treating Papilloma Virus Infection POLI, VHL, TLR3 ANPEP 520/4885RNPEP 271/4885DNPEP 269/4885
US-20100015084-A1 Compounds for Treating Papilloma Virus Infection POLI, PMAIP1, TLR3 ANPEP 663/4885RNPEP 1140/4885DNPEP 145/4885
US-20070293417-A1 Polyamides for treating human papilloma virus POLI, PARG, PARN ANPEP 211/4885RNPEP 529/4885DNPEP 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.